11:44:38 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-11-13 Kvartalsrapport 2024-Q3
2024-08-07 Kvartalsrapport 2024-Q2
2024-05-24 Ordinarie utdelning PHO 0.00 NOK
2024-05-23 Årsstämma 2024
2024-05-15 Kvartalsrapport 2024-Q1
2024-02-21 Bokslutskommuniké 2023
2023-11-08 Kvartalsrapport 2023-Q3
2023-08-09 Kvartalsrapport 2023-Q2
2023-05-10 Kvartalsrapport 2023-Q1
2023-05-04 Ordinarie utdelning PHO 0.00 NOK
2023-05-03 Årsstämma 2023
2023-02-24 Bokslutskommuniké 2022
2023-02-23 Bokslutskommuniké 2022
2022-11-02 Kvartalsrapport 2022-Q3
2022-08-10 Kvartalsrapport 2022-Q2
2022-05-11 Kvartalsrapport 2022-Q1
2022-04-29 Ordinarie utdelning PHO 0.00 NOK
2022-04-28 Årsstämma 2022
2022-02-23 Bokslutskommuniké 2021
2021-11-17 Kvartalsrapport 2021-Q3
2021-08-11 Kvartalsrapport 2021-Q2
2021-07-28 Extra Bolagsstämma 2021
2021-05-21 Ordinarie utdelning PHO 0.00 NOK
2021-05-20 Årsstämma 2021
2021-05-19 Kvartalsrapport 2021-Q1
2021-03-03 Bokslutskommuniké 2020
2020-11-10 Kvartalsrapport 2020-Q3
2020-08-18 Kvartalsrapport 2020-Q2
2020-06-11 Ordinarie utdelning PHO 0.00 NOK
2020-06-10 Årsstämma 2020
2020-05-07 Kvartalsrapport 2020-Q1
2020-02-27 Bokslutskommuniké 2019
2019-11-07 Kvartalsrapport 2019-Q3
2019-08-07 Kvartalsrapport 2019-Q2
2019-06-19 Extra Bolagsstämma 2019
2019-05-14 Kvartalsrapport 2019-Q1
2019-05-10 Ordinarie utdelning PHO 0.00 NOK
2019-05-09 Årsstämma 2019
2019-02-27 Bokslutskommuniké 2018
2018-11-08 Kvartalsrapport 2018-Q3
2018-08-08 Kvartalsrapport 2018-Q2
2018-05-23 Kvartalsrapport 2018-Q1
2018-05-11 Ordinarie utdelning PHO 0.00 NOK
2018-05-09 Årsstämma 2018
2018-02-27 Bokslutskommuniké 2017
2017-11-08 Kvartalsrapport 2017-Q3
2017-08-23 Kvartalsrapport 2017-Q2
2017-05-23 Kvartalsrapport 2017-Q1
2017-04-28 Ordinarie utdelning PHO 0.00 NOK
2017-04-27 Årsstämma 2017
2017-02-15 Bokslutskommuniké 2016
2016-11-15 Kvartalsrapport 2016-Q3
2016-08-23 Kvartalsrapport 2016-Q2
2016-05-10 Kvartalsrapport 2016-Q1
2016-04-29 Ordinarie utdelning PHO 0.00 NOK
2016-04-28 Årsstämma 2016
2016-02-11 Bokslutskommuniké 2015
2015-10-29 Kvartalsrapport 2015-Q3
2015-08-13 Kvartalsrapport 2015-Q2
2015-05-06 Kvartalsrapport 2015-Q1
2015-05-02 Ordinarie utdelning PHO 0.00 NOK
2015-04-30 Årsstämma 2015
2015-02-12 Bokslutskommuniké 2014
2014-11-06 Kvartalsrapport 2014-Q3
2014-08-26 Kvartalsrapport 2014-Q2
2014-05-28 Ordinarie utdelning PHO 0.00 NOK
2014-05-27 Årsstämma 2014
2014-05-07 Kvartalsrapport 2014-Q1
2014-02-27 Bokslutskommuniké 2013
2013-10-23 Kvartalsrapport 2013-Q3
2013-08-22 Kvartalsrapport 2013-Q2
2013-05-23 Ordinarie utdelning
2013-05-22 Årsstämma 2013
2013-04-25 Kvartalsrapport 2013-Q1
2013-02-28 Bokslutskommuniké 2012
2012-10-26 Kvartalsrapport 2012-Q3
2012-08-24 Kvartalsrapport 2012-Q2
2012-05-10 Årsstämma 2012
2012-04-26 Kvartalsrapport 2012-Q1
2012-02-16 Bokslutskommuniké 2011
2011-10-26 Kvartalsrapport 2011-Q3
2011-08-18 Kvartalsrapport 2011-Q2
2011-04-27 Kvartalsrapport 2011-Q1
2011-04-27 Årsstämma 2011
2011-02-17 Bokslutskommuniké 2010
2010-10-27 Kvartalsrapport 2010-Q3
2010-08-19 Kvartalsrapport 2010-Q2
2010-04-28 Kvartalsrapport 2010-Q1
2010-02-19 Bokslutskommuniké 2009
2009-11-26 Bonusutdelning

Beskrivning

LandNorge
ListaOB Match
SektorHälsovård
IndustriMedicinteknik
Photocure är verksamma inom medicinteknik. Bolaget specialiserar sig inom lösningar för fotodynamisk teknik. Idag används lösningarna för behandling av sjukdomar som föranlett cancer i urinblåsan och HPV. Huvudmarknaderna återfinns inom dermatologi och onkologi, där produkterna används av sjukhus och forskningsinstitut på global nivå. Bolaget grundades 1993 och har huvudkontor i Oslo, Norge.
2020-05-16 01:53:51
OSLO, Norway, 15 May 2020 -- Photocure ASA (OSE: PHO) today announced key data
was published by the 2020 American Urological Association (AUA) Annual Virtual
Meeting. Three abstracts featured Blue Light Cystoscopy (BLCT) with Cysview, and
on June 27, 2020 BLC with Cysview will be included in a virtual session of the
AUA program: "Surgical Techniques: Tips & Tricks Oncology: Bladder Cancer Blue
Light" with Dr. Anne Schuckman.

MP 73-11: Role of blue light cystoscopy in detecting invasive bladder tumor:
Data from a multi-institutional registry
https://www.auajournals.org/doi/10.1097/JU.0000000000000959.011

MP 24-06: Gender based Variations in the Detection of Bladder Cancer with Blue
Light Cystoscopy: Insights from a Multicenter Registry
https://www.auajournals.org/doi/10.1097/JU.0000000000000857.06

MP 73-02: Malignant urinary cytology of unknown origin-blue light flexible
cystoscopy at the outpatient clinic may be a valuable diagnostic tool
https://www.auajournals.org/doi/10.1097/JU.0000000000000959.02

The Role of blue light cystoscopy in detecting invasive bladder tumor: Data from
a multi-institutional registry showed that in the registry enrolled patients, a
considerable proportion of invasive bladder tumors were detected by BLC alone: A
total of 55 invasive lesions, of the 494 invasive lesions detected, were
detected only by blue light cystoscopy. The benefit of using BLC in earlier
detection of invasive bladder tumors could have an effect on the treatment
approach and potentially lead to improved survival in the high-risk population.
The study included 3514 lesions (1257 unique patients), from 9 sites in the U.S.
"Out of the overall 494 invasive lesions detected, 11% of them were only
detected by BLC alone. Also, of 47 patients with BLC-only positive invasive
lesions, 60% had concurrent CIS and 49% had an additional T1 lesion. Knowing
when these high-risk tumors are present, especially concurrently, is critical to
the optimal management of a patient's disease. We need this information in order
to make the best treatment decisions, which can have a significant impact on the
prognosis and quality of life, for our patients." says Siamak Daneshmand, MD,
Director of Urologic Oncology Associate Professor of Urology, USC Institute of
Urology.

Gender based Variations in the Detection of Bladder Cancer with Blue Light
Cystoscopy: Insights from a Multicenter Registry showed that similar to existing
evidence, BLC-alone was significantly more sensitive than WLC-alone in males
(91.1% vs 80.0%, p<0.001) and in females (86.7% vs 79.5%, p = 0.036).
Furthermore, the sensitivity with BLC between the genders was significantly
greater in males than in females (91.1% vs 86.7%, p = 0.035). Additionally, the
false-positive rate in females was significantly higher than in males in BLC
(35.9% vs 28.5%, p=0.008) and WLC (33.8% vs 27.4%, p=0.029).  These findings
highlight the differences in detection rates of NMIBC between genders, an area
that warrants further investigation, and they continue to validate the existing
evidence of increased sensitivity of BLC with Cysview in the detection of NMIBC.

Malignant urinary cytology of unknown origin ? blue light flexible cystoscopy at
the outpatient clinic, a Nordic prospective multicenter registry study, showed
that the majority of patients, 93% (27/29), stated that they preferred to have
BLC with Cysview performed with a flexible cystoscope at the outpatient clinic
versus the operating room under general anesthesia.  It was concluded that using
BLC with Cysview with a flexible cystoscope at the office may be a simple way to
solve unclear cases with malignant or suspicious urinary cytology.

"At a time when patients and physicians are seeking to ensure bladder cancer
detection and surveillance are being maintained in appropriate intervals, it is
encouraging to see more data supporting the use of BLC with Hexvix/Cysview in
the office setting." says Dan Schneider, President and CEO of Photocure.
"Additionally, Cysview for use in high-risk patients helps both physicians and
patients make difficult decisions that can impact patients' outcomes and quality
of life.  As The Bladder Cancer Company we are proud to see that more data is
being collected, and that it continues to add to the already existing evidence
that the use of Hexvix/Cysview can play a critical role in disease management."

---

About Bladder Cancer
Bladder cancer ranks as the sixth most common cancer worldwide with 1 650 000
prevalent cases (5-year prevalence rate), 550 000 new cases and almost 200 000
deaths annually in 2018.[1]

Approx. 75% of all bladder cancer cases occur in men.[1] It has a high
recurrence rate with an average of 61% in year one and 78% over five years.[2]
Bladder cancer has the highest lifetime treatment costs per patient of all
cancers.[3]

Bladder cancer is a costly, potentially progressive disease for which patients
have to undergo multiple cystoscopies due to the high risk of recurrence. There
is an urgent need to improve both the diagnosis and the management of bladder
cancer for the benefit of patients and healthcare systems alike.

Bladder cancer is classified into two types, non-muscle invasive bladder cancer
(NMIBC) and muscle-invasive bladder cancer (MIBC), depending on the depth of
invasion in the bladder wall. NMIBC remains in the inner layer of cells lining
the bladder. These cancers are the most common (75%) of all BC cases and include
the subtypes Ta, carcinoma in situ (CIS) and T1 lesions. In MIBC the cancer has
grown into deeper layers of the bladder wall. These cancers, including subtypes
T2, T3 and T4, are more likely to spread and are harder to treat.[4]
[1] Globocan. Incidence/mortality by
population. Available at: http://globocan.iarc.fr/Pages/bar_pop_sel.aspx
[2] Babjuk M, et al. Eur Urol. 2019; 76(5): 639-657
[3] Sievert KD et al. World J Urol 2009;27:295-300
[4] Bladder Cancer. American Cancer
Society. https://www.cancer.org/cancer/bladder-cancer.html

About Hexvix[®]/Cysview[®] (hexaminolevulinate HCl)

Hexvix[®]/Cysview[®] is a drug that is selectively taken up by tumor cells in
the bladder making them glow bright pink during Blue Light Cystoscopy (BLCTM).
BLCT with Hexvix[®] /Cysview[®] improves the detection of tumors and leads to
more complete resection, fewer residual tumors and better management decisions.

Cysview[®] is the tradename in the US and Canada, Hexvix[®] is the tradename in
all other markets. Photocure is commercializing Cysview[®] /Hexvix[®] directly
in the US and the Nordic region and has strategic partnerships for the
commercialization of Hexvix[®]/Cysview[®] in Europe, Canada, Australia and New
Zealand. Please refer to https://bit.ly/2wzqSQQ for further information on our
commercial partners.



All trademarks mentioned in this release are protected by law and are registered
trademarks of Photocure ASA

This press release may contain product details and information which are not
valid, or a product is not accessible, in your country. Please be aware that
Photocure does not take any responsibility for accessing such information which
may not comply with any legal process, regulation, registration or usage in the
country of your origin.

For more information, please contact:

Dan Schneider
President and CEO
Photocure ASA
Tel: + 1-609 759-6515
Email: ds@photocure.com

Erik Dahl
CFO
Photocure ASA
Tel: +4745055000
Email: ed@photocure.com

About Photocure

Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com, www.cysview.com